All In Biotech

Drug Trial Radar · NCT00810693

A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension (PAH)

Randomized, Double-blind, Placebo-controlled, Multi-centre, Multi-national Study to Evaluate the Efficacy and Safety of Oral BAY63-2521 (1 mg, 1.5 mg, 2 mg, or 2.5 mg Tid) in Patients With Symptomatic Pulmonary Arterial Hypertension (PAH)

Last checked: Nov 20, 2026Latest source record: Nov 22, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 445 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

445

Actual

Start

Dec 17, 2008

Primary completion

May 14, 2012

Study completion May 14, 2012

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Dec 18, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521 given orally for 12 weeks, in patients with symptomatic Pulmonary Arterial Hypertension (PAH).

Conditions

  • Pulmonary Hypertension

Interventions

  • Riociguat (Adempas, BAY63-2521)Drug

    BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks

  • Riociguat (Adempas, BAY63-2521)Drug

    BAY63-2521: 1.5mg tid orally for 12 weeks

  • PlaceboDrug

    Matching Placebo tid orally for 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6 Minutes Walking Distance (6MWD) - Change From Baseline to Week 12Time frame: Baseline and week 12

Locations

122 sites in 30 countries. Site status is shown where the registry gives one.

  • Site not named

    Tucson, Arizona

  • Site not named

    La Jolla, California

  • Site not named

    Los Angeles, California

  • Site not named

    Sacramento, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Louisville, Kentucky

  • Site not named

    Boston, Massachusetts

  • Site not named

    Boston, Massachusetts

  • Site not named

    Omaha, Nebraska

  • Site not named

    New York, New York

  • Site not named

    Cincinnati, Ohio

  • Site not named

    Cleveland, Ohio

  • Site not named

    Columbus, Ohio

  • Site not named

    Fairfield, Ohio

  • Site not named

    Providence, Rhode Island

  • Site not named

    Dallas, Texas

  • Site not named

    El Paso, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Capital Federal, Argentina

  • Site not named

    Darlinghurst, New South Wales, Australia

  • Site not named

    New Lambton Heights, New South Wales, Australia

  • Site not named

    Auchenflower, Queensland, Australia

  • Site not named

    Herston, Queensland, Australia

  • Royal Hobart Hospital

    Hobart, Tasmania, Australia

  • Site not named

    Prahran, Victoria, Australia

  • Site not named

    Innsbruck, Austria

  • Site not named

    Vienna, Austria

  • Site not named

    Linz, Upper Austria, Austria

  • Site not named

    Bruxelles - Brussel, Belgium

  • Site not named

    Leuven, Belgium

  • Site not named

    Rio de Janeiro, Brazil

  • Site not named

    Porto Alegre, Rio Grande do Sul, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    São Paulo, São Paulo, Brazil

  • Site not named

    Calgary, Alberta, Canada

  • Site not named

    Toronto, Ontario, Canada

  • Site not named

    Montreal, Quebec, Canada

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Shanghai, China

Showing 40 of 122 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.